Is ADAP stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Adaptimmune Therapeutics 10 years ago, but if you had invested on Wednesday 6th of May 2015 when the price was $16.00, you would have made a loss of $-15.13 per share or -94.58%
Yes, the average daily trading liquidity for Adaptimmune Therapeutics is $1.96 million. You should therefore be able to get in and out of your positions relatively fast.
Adaptimmune Therapeutics has little of the business financed by loans. This puts the company at lower risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Adaptimmune Therapeutics to be medium [0.7 out of 1]